White-Label GLP-1: How the Model Works End-to-End

White label GLP-1 is a model where an infrastructure partner runs the entire clinical machine behind a GLP-1 weight loss program (medical intake, licensed provider review, e-prescribing, pharmacy fulfillment, refills, and compliance) while your company owns the brand, the pricing, the marketing, and the customer relationship. The patient experiences one branded storefront from first click to monthly refill. Behind it, a regulated pipeline moves them from questionnaire to a state-licensed provider to a certified pharmacy to a cold-chain shipment at their door.

The reason this model exists: a GLP-1 program touches medical practice, controlled clinical workflows, pharmacy law, and state-by-state prescribing rules, and in most states a non-clinician company cannot simply hire doctors and sell semaglutide. A white label GLP-1 program solves that by plugging your brand into an existing legal and clinical stack.

This post walks the model end to end from both sides at once: what the patient sees, what the operator sees, who is legally responsible for what, and how the medication pathways actually work. If you want the founder's launch checklist instead, that is our GLP-1 weight loss brand launch guide; this piece is about how the machine itself runs.

Key takeaways

• White label GLP-1 splits the business cleanly: the operator owns the brand, pricing, marketing, and customer relationship, while the platform runs intake, provider review, prescribing, pharmacy fulfillment, and compliance.
• The patient pipeline runs branded storefront, adaptive medical intake, licensed provider review in the patient's state, e-prescription to a certified pharmacy, cold-chain shipment, then refills and titration follow-ups, all under one brand.
• Clinical decisions always belong to licensed providers and prescriptions are filled by licensed pharmacies; the MSO structure exists so a non-clinician operator can run the business side legally.
• GLP-1 medication pathways shifted materially when the FDA declared the semaglutide and tirzepatide shortages resolved across 2024 and 2025, so a durable program must be able to pivot between compounded and branded pathways.
• Vendors differ most on vertical breadth, API availability, pharmacy model, and pricing transparency; as of mid-2026, most gate pricing behind demos, with Telegra's published plan pricing a notable exception.

What does "white-label GLP-1" actually mean?

"White label" means the infrastructure provider is invisible to the patient. Someone visits your site, completes your branded intake, is reviewed by a licensed provider, and receives semaglutide or tirzepatide in packaging and portal experiences carrying your brand. The platform powering all of it never appears.

That makes white label GLP-1 different from three things it gets confused with. It is not an affiliate deal, where you send traffic to someone else's clinic and never own the customer. It is not telehealth software, which gives you forms and video calls but no providers, no pharmacy, and no legal structure. And it is not a franchise, where you run someone else's brand. In a true white label GLP-1 program, the brand and the customer list are yours; the platform is a back-end service provider.

The model is a vertical-specific application of the broader category we cover in our white label telehealth platform guide. GLP-1 is simply the highest-demand vertical to run on that infrastructure, and also the one with the most moving parts: injectables, cold-chain shipping, dose titration, and a medication supply landscape that has shifted repeatedly since 2024.

What happens end-to-end when a patient signs up?

Here is the full pipeline, using MyOrbitHealth's stack as the reference implementation. Every step is white-labeled: the patient sees your brand the whole way.

1. Branded storefront. The patient lands on your site or app, sees your pricing and your positioning, and clicks to start. You control the offer; the clinical pipeline begins behind it.

2. Adaptive medical intake. The patient completes a dynamic medical questionnaire (on MyOrbitHealth, this is Orbit Intake) covering weight history, comorbidities, medications, and contraindications like personal or family history of medullary thyroid carcinoma. The intake adapts to answers rather than marching through a fixed form, applies severity scoring, and escalates red flags: an answer suggesting an eating disorder, pregnancy, or pancreatitis history gets routed for closer clinical scrutiny or exclusion instead of sliding through to a prescription.

3. Licensed provider review in the patient's state. The completed intake goes to a provider licensed in the patient's state. Where state rules allow, the review is asynchronous: the provider evaluates the chart and decides without a live appointment. Where a state requires a synchronous encounter, the platform routes the patient to video or phone instead. MyOrbitHealth runs this on a network of 1,240+ board-certified providers covering all 50 states, with average response under six minutes during business hours. The provider decides whether GLP-1 therapy is appropriate, at what starting dose, or whether to decline and recommend alternatives. That decision is theirs alone.

4. E-prescription to a certified pharmacy. If the provider prescribes, the prescription is transmitted electronically (via OrbitRx, routed through Surescripts) to a LegitScript-certified pharmacy network spanning compounding and retail pharmacies. The pharmacy verifies the prescription and prepares the medication.

5. Cold-chain shipment. GLP-1 injectables are temperature-sensitive, so fulfillment means insulated cold-chain packaging shipped to the patient's door with tracking surfaced under your brand. Fulfillment quality (shipping time, temperature integrity, replacement handling) is where patients form their opinion of your program, which is why the pharmacy layer deserves real diligence; we cover how to evaluate it in our guide to compounding pharmacy partnerships.

6. Refills, follow-ups, and titration. GLP-1 therapy is longitudinal. Doses typically titrate upward over the first months, side effects need managing, and refills recur monthly. The platform handles refill requests, provider check-ins, dose-change reviews, and patient messaging inside OrbitOS, still under your brand. This step is the business: GLP-1 economics are subscription economics, and retention lives or dies on how smooth months two through twelve feel.

From the patient's perspective, all six steps are one continuous branded experience. From yours, they are a pipeline you observe and monetize but do not clinically operate.

What does the operator own and see?

The operator's side of the model is deliberately non-clinical. You own four things outright: the brand, the pricing, the marketing, and the customer relationship. You decide what the program costs, how it is positioned, which channels acquire patients, and what the lifecycle communication feels like. Your customer list and marketing data are yours, and that should be in the contract.

What you see is the operational console. In OrbitOS, an operator gets a real-time view of patients, encounters, prescriptions, and fulfillment status, with role-based access and a full HIPAA audit trail. You can watch a cohort move through intake, see approval outcomes, track refill rates, and reconcile volumes, without touching clinical decision-making.

There are two integration modes, and choosing between them is a real fork:

• Hosted white-label clinic. The platform hosts the branded storefront, intake, and patient portal. Fastest path; you point a domain and drive traffic.
• Embedded via API. If you already have a product (a fitness app, an e-commerce brand, an employer platform), MyOrbitHealth's REST API, webhooks, and React SDK let you embed intake, encounter status, and prescription events directly into your own front end. Webhooks push pipeline events (intake completed, prescription written, shipment out) into your systems so your CRM and lifecycle messaging stay in sync. As of mid-2026, only Telegra among direct competitors also offers a public API, and none pairs one with a React SDK, which makes the developer surface a genuine differentiator if telehealth needs to live inside something you have already built.

Either way, the division holds: you run the demand side and the customer experience shell; the platform runs the regulated pipeline inside it.

Who is legally responsible for what?

This is the part of the model that makes non-lawyers nervous, so here is the plain-language split.

Most US states enforce some version of the corporate practice of medicine doctrine: a company without a medical license cannot employ physicians or direct clinical care. The standard structure is the MSO model. A physician-owned professional entity employs or contracts the licensed providers and owns every clinical decision: who is eligible, what gets prescribed, when to titrate, when to decline. A management services organization (the platform side) provides everything non-clinical: software, administration, pharmacy logistics, and support. Your brand contracts into this structure rather than building it.

The responsibility map looks like this. Providers are responsible for medical judgment and are accountable to their state boards. Pharmacies are responsible for dispensing legally and are accountable to boards of pharmacy and, for compounders, FDA oversight. The platform is responsible for the software, the network, and the compliance architecture (HIPAA with a BAA, audit trails, EPCS identity proofing). The operator is responsible for truthful marketing and the commercial side, which is not nothing: weight loss advertising claims are regulated, and payment processors and ad platforms typically expect LegitScript certification before a telehealth brand can advertise or take cards.

Provider independence is the load-bearing wall. A legitimate platform will never let an operator influence prescribing decisions, set approval targets, or pressure providers on outcomes, and you should walk away from any vendor that suggests otherwise. We unpack the structure in depth in our MSO model and telehealth compliance guide.

This is general information, not legal advice.

What are the medication-pathway realities?

Anyone selling you a GLP-1 program without discussing supply pathways is skipping the hard part. There are two:

Branded medications. Semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) from the original manufacturers. FDA-approved products with predictable quality, but historically expensive for cash-pay patients, with access shaped by manufacturer programs and, increasingly, the manufacturers' own direct-to-patient pricing channels.

Compounded medications. During the well-documented shortages of 2022 through 2024, compounding pharmacies could legally prepare versions of semaglutide and tirzepatide under shortage-related provisions, and much of the DTC GLP-1 boom ran on that pathway at a much lower cash price. Then the ground shifted: the FDA declared the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved in early 2025, with wind-down deadlines through 2025 that sharply narrowed when compounders can produce copies of those drugs. Compounding has not disappeared (it remains legal in specific circumstances, such as clinically necessary customization for an individual patient), but the broad shortage-era model is gone, and regulatory scrutiny of GLP-1 compounding is materially higher than it was.

The operational lesson is not "pick the right pathway." It is "build so you can pivot." The pathway that is viable today may narrow next year, and programs hard-wired to a single compounding pharmacy took real damage when the shortage designations ended. This is why pharmacy-network design matters: MyOrbitHealth's LegitScript-certified network spans both compounding and retail pharmacies, so a program can route prescriptions down whichever pathway is legal and appropriate for each patient as conditions change. Whatever platform you evaluate, ask directly how it handled the 2024–2025 transition and what happens to your patients if a pathway closes.

How do white-label GLP-1 providers differ?

The vendors look similar on landing pages and diverge in the mechanics. As of mid-2026, the shortlist founders actually compare, across the dimensions that matter:

All competitor characterizations are as of mid-2026, per each vendor's published materials; verify current terms directly. The honest summary: if published plan pricing is your deciding factor, Telegra publishes it. If you are an enterprise, OpenLoop is built for you. If you expect to start with GLP-1 and expand into TRT, hormones, or women's health, or you need telehealth inside an existing product via API, breadth and the developer surface are the deciding factors. Our ranked breakdown of the best white label telehealth platforms scores each vendor in more depth.

How fast can you launch?

Faster than almost anything else in healthcare, because the slow parts already exist. The provider network is credentialed, the pharmacy relationships are live, the MSO structure is standing, and the software is multi-tenant. What remains is configuration: branding the storefront and intake, setting your treatment catalog and pricing, connecting billing, and completing compliance onboarding (plus API integration work if you embed rather than host).

That typically puts launch on existing infrastructure in the weeks-to-a-few-months range, versus a year or more to assemble providers, pharmacies, software, and legal structure yourself. Your timeline drivers are mostly on your side of the fence: how fast you finalize brand and pricing, whether you pursue LegitScript certification for advertising, and how much custom integration you take on. The full sequence, from entity setup through first marketing dollar, is laid out step by step in the GLP-1 launch playbook, and you can see how MyOrbitHealth packages the infrastructure on the platform page.

Frequently asked questions

Do I need a medical license to run a white label GLP-1 program?

No. Licensed providers within the platform's affiliated physician-owned professional entities make every clinical decision, and licensed pharmacies dispense the medication. You operate the brand, marketing, and customer relationship under an MSO structure that keeps the business side legally separate from clinical practice. Rules vary by state, so reputable platforms build this with healthcare counsel.

Can patients in any state use a white label GLP-1 program?

Coverage depends on the platform's provider network, since medical licensure is state by state. A 50-state network lets you market nationally, while gaps force geo-restricted advertising. State rules also differ on whether an asynchronous review is enough or a live video or phone visit is required before prescribing, and a good platform routes each patient through the modality their state requires automatically.

Is compounded semaglutide still available for white label GLP-1 programs?

Only in narrow circumstances. After the FDA declared the tirzepatide and semaglutide shortages resolved across late 2024 and early 2025, broad compounding of copies of those drugs wound down, though compounding remains legal in specific situations such as clinically necessary customization for an individual patient. Durable programs are built to route between compounded and branded pathways as regulations and supply evolve.

Who handles GLP-1 side effects and dose changes?

The licensed providers do. GLP-1 therapy involves titration over the first months and commonly gastrointestinal side effects, so follow-up encounters, dose-change reviews, and patient messaging run through the platform's clinical workflow under your brand. The operator sees the activity in the console but never makes clinical calls.

How is a white label GLP-1 program different from reselling or affiliate marketing?

In an affiliate model you send traffic to someone else's clinic, earn a commission, and never own the customer. In a white label GLP-1 program you own the brand, set the pricing, keep the customer list, and control the entire front-end experience, while the platform runs the regulated clinical and pharmacy pipeline behind it. The difference is owning an asset versus renting out your audience.

What does white label GLP-1 infrastructure cost?

Most vendors quote privately, with deals typically combining a setup fee, a monthly platform fee, and per-consult or per-prescription components, plus medication costs that may or may not be passed through at cost. As one published reference point, Telegra lists plans at $3,000–$6,000 per month plus a $5,000–$10,000 one-time onboarding fee, with consultation fees billed separately and no per-prescription or transaction fees, as of mid-2026. Model total cost per active patient per month at your projected volume, including any medication markup.

Ready to see the machine run under your brand?

If you want the intake, provider, pharmacy, and compliance layers handled while you own the brand and the customers, MyOrbitHealth runs the entire GLP-1 pipeline behind your storefront, hosted or via API. Book a demo with MyOrbitHealth to walk through the end-to-end flow with your brand on it.